WCLC: Positive data highlights NSCLC pipeline
At the recent IASLC World Conference on Lung Cancer, HCM published positive proof of concept data in NSCLC on key assets fruquintinib and epitinib. Affirmative data not only translates to further pipeline progression but critically underpins the R&D effort at HCM, fuelling the prospects of a fruquintinib regulatory filing in China in 2018. In 2017 we anticipate the initiation of three more pivotal trials, further data from the mid- to late-stage pipeline, including savolitinib data (papillary renal cell carcinoma, PRCC, and non-small cell lung cancer, NSCLC), and importantly potential China/US NDA submissions. We value HCM at $2.4bn or £32.2 share.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.